Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STXS Stock Forecast 2025-2026
$2.37
Current Price
$221.18M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to STXS Price Targets
+111.0%
To High Target of $5.00
+68.8%
To Median Target of $4.00
+68.8%
To Low Target of $4.00
STXS Price Momentum
-2.5%
1 Week Change
-16.8%
1 Month Change
+5.8%
1 Year Change
+3.9%
Year-to-Date Change
-34.0%
From 52W High of $3.59
+53.9%
From 52W Low of $1.54
📊 TOP ANALYST CALLS
Did STXS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stereotaxis is one of their latest high-conviction picks.
Latest STXS Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, STXS has a bullish consensus with a median price target of $4.00 (ranging from $4.00 to $5.00). The overall analyst rating is N/A (N/A/10). Currently trading at $2.37, the median forecast implies a 68.8% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Wittes at Roth MKM, projecting a 111.0% upside. Conversely, the most conservative target is provided by Kyle Bauser at Roth Capital, suggesting a 68.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STXS Analyst Ratings
4
Buy
0
Hold
0
Sell
STXS Price Target Range
Low
$4.00
Average
$4.00
High
$5.00
Current: $2.37
Latest STXS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STXS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 12, 2025 | Roth Capital | Kyle Bauser | Buy | Reiterates | $4.00 |
| Nov 5, 2025 | Roth Capital | Kyle Bauser | Buy | Reinstates | $4.00 |
| Mar 5, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $4.00 |
| Mar 5, 2024 | Roth MKM | Jason Wittes | Buy | Reiterates | $5.00 |
| Jan 10, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $5.00 |
| Mar 6, 2023 | B. Riley Securities | Neil Chatterji | Buy | Maintains | $5.50 |
| Mar 6, 2023 | Piper Sandler | Adam Maeder | Overweight | Maintains | $5.00 |
| Mar 6, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $4.00 |
| Nov 11, 2022 | Cowen & Co. | Joshua Jennings | Outperform | Maintains | $5.00 |
| Sep 2, 2022 | B. Riley Securities | Buy | Initiates | $N/A | |
| Jul 12, 2022 | Aegis Capital | Nathan Weinstein | Buy | Initiates | $6.00 |
| Jun 23, 2022 | B. Riley Securities | Buy | Initiates | $N/A | |
| Jan 5, 2022 | Craig-Hallum | Buy | Initiates | $N/A | |
| Jan 5, 2022 | Loop Capital | Buy | Initiates | $N/A | |
| May 26, 2021 | Piper Sandler | Overweight | Initiates | $N/A | |
| Sep 8, 2020 | Northland Capital Markets | Outperform | Initiates | $N/A | |
| Apr 9, 2020 | Cowen & Co. | Outperform | Initiates | $N/A |
Stereotaxis Inc. (STXS) Competitors
The following stocks are similar to Stereotaxis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
STXS
Stereotaxis
mkt cap
224.91M
Stereotaxis Inc. (STXS) Financial Data
Stereotaxis Inc. has a market capitalization of $221.18M with a P/E ratio of -7.9x. The company generates $30.08M in trailing twelve-month revenue with a -78.6% profit margin.
Revenue growth is -18.8% quarter-over-quarter, while maintaining an operating margin of -69.7% and return on equity of -170.2%.
Valuation Metrics
Market Cap
$221.18M
Enterprise Value
$220.59M
P/E Ratio
-7.9x
PEG Ratio
0.6x
Price/Sales
7.5x
Growth & Margins
Revenue Growth (YoY)
-18.8%
Gross Margin
+54.9%
Operating Margin
-69.7%
Net Margin
-78.6%
EPS Growth
-18.8%
Financial Health
Cash/Price Ratio
+4.8%
Current Ratio
1.3x
Debt/Equity
48.4x
ROE
-170.2%
ROA
-26.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stereotaxis Inc. (STXS) Business Model
About Stereotaxis Inc.
What They Do
Develops robotic systems for minimally invasive surgery.
Business Model
The company generates revenue through the development and commercialization of its robotic navigation technologies, particularly the Niobe Magnetic Navigation System. This system enhances the precision and safety of cardiac arrhythmia treatments, resulting in increased adoption by hospitals and medical centers specializing in interventional cardiology.
Additional Information
Stereotaxis is based in St. Louis, Missouri, and is focused on advancing robotic surgery technology, contributing to the growth and innovation of the broader medical device market.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
139
CEO
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Country
United States
IPO Year
2004
Website
www.stereotaxis.comStereotaxis Inc. (STXS) Latest News & Analysis
Latest News
Quick Summary
Stereotaxis (NYSE: STXS) will participate in the Piper Sandler 37th Annual Healthcare Conference, highlighting its role in surgical robotics for minimally invasive procedures.
Why It Matters
Stereotaxis's participation in a major healthcare conference may signal potential growth opportunities, increased visibility, and investor interest in its surgical robotics innovations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Stereotaxis, Inc. (STXS) will hold its Q3 2025 earnings call on November 11, 2025, at 4:30 PM EST, featuring CEO David Fischel and CFO Kimberly Peery.
Why It Matters
Stereotaxis' Q3 earnings call indicates upcoming financial performance insights, critical for assessing future growth potential and investment risk in the company.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Stereotaxis (NYSE: STXS) reported its third-quarter financial results for 2025, continuing its role as a leader in surgical robotics for minimally invasive procedures.
Why It Matters
Stereotaxis' Q3 financial results can influence stock performance, reflecting company growth, profitability, and market position in surgical robotics, impacting investor sentiment and decisions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Stereotaxis Inc. (STXS) reported a quarterly loss of $0.03 per share, better than the expected loss of $0.06, and an improvement from a loss of $0.08 per share a year prior.
Why It Matters
Stereotaxis Inc.'s smaller-than-expected loss signals improving financial performance, potentially boosting investor confidence and impacting stock value positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Stereotaxis has received FDA clearance for its GenesisX robotic system, which aims to enhance hospital adoption and drive growth.
Why It Matters
FDA clearance for GenesisX enhances Stereotaxis' market position, potentially increasing revenue and hospital partnerships, which can drive stock value and investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Stereotaxis (NYSE: STXS) announced FDA 510(k) clearance for its GenesisX™ robotic system, enhancing its position in surgical robotics for minimally invasive procedures.
Why It Matters
FDA clearance for Stereotaxis' GenesisX™ robotic system enhances its market position, potentially boosting sales and investor confidence in future revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About STXS Stock
What is Stereotaxis Inc.'s (STXS) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Stereotaxis Inc. (STXS) has a median price target of $4.00. The highest price target is $5.00 and the lowest is $4.00.
Is STXS stock a good investment in 2026?
According to current analyst ratings, STXS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STXS stock?
Wall Street analysts predict STXS stock could reach $4.00 in the next 12 months. This represents a 68.8% increase from the current price of $2.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stereotaxis Inc.'s business model?
The company generates revenue through the development and commercialization of its robotic navigation technologies, particularly the Niobe Magnetic Navigation System. This system enhances the precision and safety of cardiac arrhythmia treatments, resulting in increased adoption by hospitals and medical centers specializing in interventional cardiology.
What is the highest forecasted price for STXS Stereotaxis Inc.?
The highest price target for STXS is $5.00 from Jason Wittes at Roth MKM, which represents a 111.0% increase from the current price of $2.37.
What is the lowest forecasted price for STXS Stereotaxis Inc.?
The lowest price target for STXS is $4.00 from Kyle Bauser at Roth Capital, which represents a 68.8% increase from the current price of $2.37.
What is the overall STXS consensus from analysts for Stereotaxis Inc.?
The overall analyst consensus for STXS is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are STXS stock price projections?
Stock price projections, including those for Stereotaxis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 4:14 AM UTC